Download PDF
Nervenheilkunde 2008; 27(09): 789-793
DOI: 10.1055/s-0038-1627218
Originaler Artikel
Schattauer GmbH

Langkettige mehrfach ungesättigte Fettsäuren – eine zusätzliche Behandlungsmöglichkeit bei Kindern mit ADHS?

Polyunsaturated long-chain fatty acids – a treatment option for children with attention-deficit/ hyperactivity disorder?
U. Weiland
1   Universität Ulm, Transferzentrum für Neurowissenschaften und Lernen (Leitung: Prof. Dr. med. Dr. phil. M. Spitzer)
,
K. Widenhorn-Müller
1   Universität Ulm, Transferzentrum für Neurowissenschaften und Lernen (Leitung: Prof. Dr. med. Dr. phil. M. Spitzer)
› Author Affiliations
Further Information

Publication History

Eingegangen am: 04 July 2008

angenommen am: 04 July 2008

Publication Date:
22 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Von der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) sind in Deutschland 2 bis 7% der Kinder und Jugendlichen betroffen. Bei mindestens einem Drittel der diagnostizierten Kinder persistieren die ADHS-Symptome bis ins Erwachsenenalter. Die häufigste medikamentöse Behandlungsmethode ist die Psychostimulanzientherapie, die aber nicht unumstritten ist und von vielen Eltern abgelehnt wird. Seit etwa 20 Jahren wird diskutiert, ob ein Mangel an langkettigen mehrfach ungesättigten Fettsäuren (LCPUFAs) ein Risikofaktor für die Entstehung von ADHS sein könnte.

Das Ziel des vorliegenden Übersichtsartikels ist eine Zusammenfassung der Ergebnisse aus Interventionsstudien, die Hinweise zur Wirksamkeit einer LCPUFA-Supplementierung als Therapieoption bei Kindern mit ADHS zu geben.

Summary

In Germany, 2 to 7% of children and adolescents are affected by attention-deficit/hyperactivity disorder (ADHD). At least one third of the diagnosed children continue to manifest ADHD symptoms into adult life. Stimulant medication is the most frequently used treatment procedure, although it is controversial and not accepted by all parents. Fatty acid deficiency was first proposed as a possible risk factor for the development of ADHD more than 20 years ago.

The objective of the current article is to review the evidence for the benefit of LCPUFA supplementation as a therapy option for children with ADHD.

Schlüsselwörter

Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung - langkettige mehrfach ungesättigte Fettsäuren - Interventionsstudien

Keywords

Attention-deficit/hyperactivity disorder - polyunsaturated long-chain fatty acids - intervention studies
 

  • Literatur

  • 1 Antalis C, Stevens L, Campbell M, Pazdro R, Ericson K, Burgess J. Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins Leukotrienes and Essential Fatty Acids 2006; 75 4–5 299-308.
    CrossrefPubMedGoogle Scholar
  • 2 Biedermann J, Faraone S. Attention-deficit hyperactivity disorder. The Lancet 2005; 366: 237-248.
    CrossrefPubMedGoogle Scholar
  • 3 Blanz B, Döpfner M, Fleischmann J, Herpertz-Dahlmann B, Huss M, Martinius J. et al. Stellungnahme zur „Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS)“. Deutsches Ärzteblatt 2005; 102: 3609-3616.
    Google Scholar
  • 4 Brookes K, Chen W, Xu X, Taylor E. et al. Association of fatty acid desaturase genes with attentiondeficit/ hyperactivity disorder. Biological Psychology 2006; 60 (Suppl. 10) 1053-1061.
    CrossrefPubMedGoogle Scholar
  • 5 Burdge G, Calder P. Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod. Nutr. Dev 2005; 45: 581-597.
    CrossrefPubMedGoogle Scholar
  • 6 Chen JR, Hsu SF, Hsu CD, Hwang LH, Yang SC. Dietary patterns and blood fatty acid composition in children with attention deficit hyperactivity disorder in Taiwan. The Journal of Nutritional Biochemistry 2004; 15 (Suppl. 08) 467-472.
    CrossrefPubMedGoogle Scholar
  • 7 Colquhoun I, Bunday S. A lack of essential fatty acids as a possible cause of hyperactivity in children. Med Hypotheses 1981; 7 (Suppl. 05) 673-679.
    CrossrefPubMedGoogle Scholar
  • 8 Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder – a placebo-controlled doubleblind study. Eur J Clin Nutr 2004; 58: 467-473.
    CrossrefPubMedGoogle Scholar
  • 9 Mitchell E, Aman M, Turbott S, Manku M. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clinical Pediatrics 1987; 26 (Suppl. 08) 406-411.
    CrossrefPubMedGoogle Scholar
  • 10 Richardson AJ, Puri BK. A randomized doubleblind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog in Neuro- Psychopharmacology & Biological Psychiatry 2002; 26: 233-239.
    Google Scholar
  • 11 Richardson AJ, Montgomery P. The Oxford-Durham Study: A randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 2005; 115 (Suppl. 05) 1360-1366.
    CrossrefPubMedGoogle Scholar
  • 12 Ross B, McKenzie I, Glen I, Bennett C. Increased levels of ethane, a non-invasive marker of N-3 fatty acid oxidation, in breath of children with attention deficit hyperactivity disorder. Nutr Neurosci 2003; 6 (Suppl. 05) 277-281.
    CrossrefPubMedGoogle Scholar
  • 13 Shaw P, Eckstrand K, Sharp W, Blumenthal J, Lerch J, Greestein D. et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. PNAS 2007; 104 (Suppl. 49) 19649-19654.
    CrossrefPubMedGoogle Scholar
  • 14 Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics 2007; 28 (Suppl. 02) 82-91.
    CrossrefPubMedGoogle Scholar
  • 15 Sorgi P, Hallowell E, Hutchins H, Sears B. Effects of an open-label pilot study with high-dose EPA/ DHA concentrates on plasma phopholipids and behavior in children with attention deficit hyperactivity disorder. Nurition Journal. 2007 6(16).
    PubMedGoogle Scholar
  • 16 Spencer T, Biedermann J, Mick E. Attention-Deficit/ Hyperactivity Disorder: Diagnosis, Lifespan, Comorbidities, and Neurobiology. J Pediatric Psychology 2007; 32 (Suppl. 06) 631-642.
    Google Scholar
  • 17 Stevens L, Zentall S, Deck J, Abate M, Watkins B, Lipp S. et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr 1995; 62: 761-768.
    CrossrefPubMedGoogle Scholar
  • 18 Stevens L, Zhang W, Peck L, Kuczek T, Grevstad N, Mahon A. et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003; 38 (Suppl. 10) 1007-1021.
    CrossrefPubMedGoogle Scholar
  • 19 Voigt R, Llorente A, Jensen C, Fraley J, Berretta M, Heird W. A randomized, double-blind, placebo- controlled trial of decosahexaenoic acid supplementation in children with attention-deficit/ hyperactivity disorder. J Pediatr 2001; 139 (Suppl. 02) 189-196.
    CrossrefPubMedGoogle Scholar
  • 20 Abler B, Vasic N. Rolle des zentralen dopaminergen Systems bei psychiatrischen Erkrankungen – Schizophrenie, Depression, Manie und ADHS. Nervenheilkunde 2007; 26: 141-149.
    Article in Thieme ConnectGoogle Scholar
  • 21 Walitza S. et al. Genetik und Bildgebung bei Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörungen. Nervenheilkunde 2006; 25: 421-429.
    Article in Thieme ConnectGoogle Scholar